Primary |
Drug Use For Unknown Indication |
25.1% |
Product Used For Unknown Indication |
18.2% |
Cancer Pain |
14.8% |
Pain |
14.4% |
Drug Abuser |
3.9% |
Prophylaxis |
3.8% |
Back Pain |
3.7% |
Drug Abuse |
2.8% |
Constipation |
2.4% |
Insomnia |
1.3% |
Depression |
1.2% |
Nausea |
1.2% |
Hypertension |
1.2% |
Nutritional Support |
1.0% |
Breakthrough Pain |
1.0% |
Lung Neoplasm Malignant |
0.9% |
Renal Cell Carcinoma |
0.8% |
Fluid Replacement |
0.8% |
Prophylaxis Of Nausea And Vomiting |
0.8% |
Analgesic Therapy |
0.7% |
|
Respiratory Arrest |
19.4% |
Completed Suicide |
8.7% |
Cardio-respiratory Arrest |
8.6% |
Death |
8.2% |
Vomiting |
7.8% |
Somnolence |
6.0% |
Substance Abuse |
5.1% |
Drug Abuse |
5.0% |
Unresponsive To Stimuli |
4.3% |
Delirium |
3.3% |
Toxicity To Various Agents |
3.3% |
Overdose |
3.1% |
Poisoning |
2.8% |
Cardiac Arrest |
2.6% |
Serotonin Syndrome |
2.6% |
Drug Abuser |
1.9% |
Nausea |
1.9% |
Pharmaceutical Product Complaint |
1.9% |
Drug Dependence |
1.8% |
Intentional Drug Misuse |
1.8% |
|
Secondary |
Product Used For Unknown Indication |
24.6% |
Drug Use For Unknown Indication |
21.0% |
Cancer Pain |
15.9% |
Pain |
10.8% |
Prophylaxis |
5.5% |
Constipation |
3.3% |
Back Pain |
3.2% |
Depression |
2.2% |
Insomnia |
1.5% |
Breakthrough Pain |
1.5% |
Analgesic Therapy |
1.4% |
Hypertension |
1.3% |
Prophylaxis Of Nausea And Vomiting |
1.2% |
Fibromyalgia |
1.1% |
Breast Cancer |
1.1% |
Ovarian Cancer |
0.9% |
Malignant Neoplasm Of Renal Pelvis |
0.9% |
Anxiety |
0.9% |
Ill-defined Disorder |
0.9% |
Diabetes Mellitus |
0.8% |
|
Respiratory Arrest |
15.9% |
Completed Suicide |
9.3% |
Death |
7.7% |
Somnolence |
7.5% |
Toxicity To Various Agents |
6.9% |
Vomiting |
6.1% |
Drug Abuse |
6.0% |
Drug Toxicity |
5.0% |
Cardio-respiratory Arrest |
4.6% |
Delirium |
4.1% |
Multiple Drug Overdose |
3.4% |
Cardiac Arrest |
3.3% |
Intentional Drug Misuse |
2.9% |
Poisoning |
2.9% |
Nausea |
2.8% |
White Blood Cell Count Decreased |
2.7% |
Overdose |
2.7% |
Insomnia |
2.5% |
Unresponsive To Stimuli |
2.1% |
Pain |
1.6% |
|
Concomitant |
Product Used For Unknown Indication |
26.3% |
Drug Use For Unknown Indication |
15.5% |
Pain |
15.0% |
Multiple Myeloma |
5.2% |
Hypertension |
3.9% |
Depression |
3.5% |
Nausea |
3.5% |
Prophylaxis |
3.0% |
Rheumatoid Arthritis |
2.9% |
Constipation |
2.7% |
Back Pain |
2.7% |
Anxiety |
2.3% |
Non-small Cell Lung Cancer |
2.2% |
Insomnia |
2.0% |
Crohn's Disease |
1.9% |
Breast Cancer |
1.8% |
Gastrooesophageal Reflux Disease |
1.5% |
Osteoporosis |
1.4% |
Diabetes Mellitus |
1.4% |
Breakthrough Pain |
1.3% |
|
Vomiting |
16.9% |
Weight Decreased |
9.6% |
Death |
7.2% |
Pain |
6.3% |
Wrong Technique In Drug Usage Process |
5.3% |
Pneumonia |
5.1% |
Pyrexia |
4.7% |
Pulmonary Embolism |
4.5% |
Weight Increased |
4.3% |
Nausea |
4.2% |
White Blood Cell Count Decreased |
4.1% |
Thrombocytopenia |
3.8% |
Urinary Tract Infection |
3.2% |
Renal Failure |
3.2% |
Dyspnoea |
3.2% |
Drug Ineffective |
3.1% |
Renal Failure Acute |
3.0% |
Rash |
2.9% |
Tremor |
2.8% |
Sepsis |
2.6% |
|
Interacting |
Product Used For Unknown Indication |
33.9% |
Drug Use For Unknown Indication |
10.1% |
Pain |
10.1% |
Depression |
6.2% |
Neuralgia |
6.2% |
Osteomyelitis Bacterial |
6.2% |
Pain In Extremity |
6.2% |
Antiemetic Supportive Care |
4.7% |
Cancer Pain |
2.3% |
Arthralgia |
1.9% |
Fibromyalgia |
1.9% |
Diabetes Mellitus |
1.6% |
Ovarian Cancer |
1.6% |
Psoriatic Arthropathy |
1.6% |
Cardiac Disorder |
1.2% |
Smoking Cessation Therapy |
1.2% |
Back Pain |
0.8% |
Constipation |
0.8% |
Deep Vein Thrombosis |
0.8% |
Hypertension |
0.8% |
|
Drug Interaction |
14.3% |
Inhibitory Drug Interaction |
12.7% |
Drug Toxicity |
7.9% |
Miosis |
6.3% |
Surgery |
6.3% |
Toxicity To Various Agents |
6.3% |
Urinary Retention |
6.3% |
Renal Cell Carcinoma Stage Unspecified |
4.8% |
Bronchopneumonia |
3.2% |
Fall |
3.2% |
Hallucination |
3.2% |
Neurotoxicity |
3.2% |
Respiratory Depression |
3.2% |
Sedation |
3.2% |
Serotonin Syndrome |
3.2% |
Subdural Haematoma |
3.2% |
Swelling |
3.2% |
Vomiting |
3.2% |
Alcohol Interaction |
1.6% |
Drug Administered At Inappropriate Site |
1.6% |
|